| 1  | Genome-wide fine-mapping improves identification of causal variants   |
|----|---|
| 2  |   |
| 3  | Yang Wu <sup>1,2,*</sup> , Zhili Zheng <sup>2,3,4</sup> , Loic Thibaut <sup>2</sup> , Michael E. Goddard <sup>5,6</sup> , Naomi R. Wray <sup>2,7</sup> , Peter M. |
| 4  | Visscher <sup>2,8</sup> , Jian Zeng <sup>2,*</sup>  |
| 5  |   |
| 6  | <sup>1</sup> Institute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, China  |
| 7  | $^{\rm 2}$ Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland,  |
| 8  | Australia   |
| 9  | <sup>3</sup> Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge,   |
| 10 | Massachusetts, USA  |
| 11 | <sup>4</sup> Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge,  |
| 12 | Massachusetts, USA  |
| 13 | <sup>5</sup> Faculty of Veterinary and Agricultural Science, University of Melbourne, Parkville, Victoria,  |
| 14 | Australia   |
| 15 | <sup>6</sup> Biosciences Research Division, Department of Economic Development, Jobs, Transport and   |
| 16 | Resources, Bundoora, Victoria, Australia  |
| 17 | <sup>7</sup> Department of Psychiatry, University of Oxford, Oxford, UK   |
| 18 | <sup>8</sup> Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department   |
| 19 | of Population Health, University of Oxford, Oxford, UK  |
| 20 |   |
| 21 | * Correspondence: Yang Wu ( <u>yang.wu@wchscu.edu.cn</u> ), Jian Zeng (j <u>.zeng@uq.edu.au</u> )   |

### 22 Abstract

Fine-mapping refines genotype-phenotype association signals to identify causal variants 23 underlying complex traits. However, current methods typically focus on individual genomic 24 segments without considering the global genetic architecture. Here, we demonstrate the 25 advantages of performing genome-wide fine-mapping (GWFM) and develop methods to facilitate 26 GWFM. In simulations and real data analyses, GWFM outperforms current methods in error 27 control, mapping power and precision, replication rate, and trans-ancestry phenotype prediction. 28 29 For 48 well-powered traits in the UK Biobank, we identify causal variants that collectively explain 17% of the SNP-based heritability, and predict that fine-mapping 50% of that would require 2 30 million samples on average. We pinpoint a known causal variant, as proof-of-principle, at FTO for 31 body mass index, unveil a hidden secondary variant with evolutionary conservation, and identify 32 new missense causal variants for schizophrenia and Crohn's disease. Overall, we analyse 600 33 34 complex traits with 13 million SNPs, highlighting the efficacy of GWFM with functional 35 annotations.

## 36 Introduction

Genome-wide association studies (GWAS) have successfully identified numerous genetic variants
associated with complex traits<sup>1-3</sup>. However, the underlying casual variants for these traits are
largely unknown. In a standard GWAS, the trait-variant associations are tested one at a time,
leading to the discovery of clusters of mutually correlated marginal-association signals due to
linkage disequilibrium (LD) between SNPs<sup>4</sup>. While post-GWAS methods such as LD clumping<sup>5</sup> or
COJO<sup>6</sup> are used to identify independently significant association signals, SNPs prioritised by these
methods are not necessarily the causal variants<sup>7,8</sup>.

44

Statistical fine-mapping, often employing a Bayesian mixture model (BMM), offers a direct 45 approach to narrow down the likely causal variants<sup>9</sup>. In contrast to GWAS, which test marginal 46 effects, fine-mapping aims to detect joint-association signals for causal inference, where the 47 48 strength of joint association is assessed using the posterior inclusion probability (PIP). PIP is the probability of a SNP being included with a nonzero effect in the model, which, in theory, controls 49 false discovery rate (FDR)<sup>10</sup>. Due to the computational burden and complexity of test hypotheses, 50 current fine-mapping methods focus on genome-wide significant loci only or consider one 51 genomic region at a time (e.g., a LD block), in isolation from the rest of the genome<sup>11-14</sup>. Methods 52 differ mainly in the algorithm used to derive PIP. For example, FINEMAP<sup>12</sup> utilizes a shotgun 53 54 stochastic search algorithm to explore possible causal configurations, and computes the PIP by 55 averaging over those with non-negligible probabilities. SuSiE<sup>11</sup> and SuSiE-RSS<sup>14</sup> assume a sparse effect model and employ an iterative Bayesian stepwise selection approach to estimate the overall 56 effect of each SNP by summing up multiple singe-effect vectors. SuSiE-Inf<sup>13</sup> and FINEMAP-Inf<sup>13</sup> 57 further extend the two models to include an infinitesimal component for improved modelling of 58 polygenic architecture within a locus. 59

60

Despite being widely used, region-specific analysis has limitations. First, the prior specification of genetic architecture is crucial, but is often conservatively predetermined in these analysis<sup>11,12,15</sup> (e.g., prior probability of association set to one over the number of SNPs in the region), which can result in reduced power. Second, fine-mapping can benefit from incorporating functional genomic annotations<sup>16-18</sup>, but region-specific methods require step-wise procedures so that GWAS data and functional annotations are not modelled jointly<sup>19</sup>. Third, none of the current methods estimates the power of identifying the causal variants for a trait, which is critical to inform the

experimental design of a prospective study (such a power analysis is available in GWAS<sup>20</sup> but not
in fine-mapping).

70

These limitations of current fine-mapping methods can be addressed through conducting a fine-71 mapping analysis using a genome-wide Bayesian mixture model (GBMM). GBMMs, which have 72 been widely used for predicting breeding values in agricultural species<sup>21-23</sup> and complex trait 73 74 phenotypes in humans<sup>24-27</sup>, have recently emerged as a method of GWFM<sup>28,29</sup>. Compared to 75 conventional GWAS and region-specific fine-mapping approaches, GBMMs consider genomewide SNPs simultaneously, which are all utilised to estimate the genetic architecture and 76 77 functional prior<sup>27,28</sup>. For example, SNPs with the same class of functional annotation are present 78 across the genome. By considering all SNPs jointly, the importance of a functional annotation in a local genomic region can be prioritised based on the evidence for association as a class across the 79 80 genome. In GBMMs, Markov chain Monte Carlo (MCMC) sampling is often used for posterior inference, which is asymptotically exact and superior to the variational inference regarding 81 accuracy<sup>30</sup>, but computationally challenging when analysing high-density SNPs. Fortunately, 82 recent advances in methodology, such as SBayesRC<sup>27</sup>, have allowed fitting all common SNPs 83 efficiently in a MCMC-based GBMM. Moreover, GBMMs estimate the polygenicity and variant 84 effect size distribution<sup>22,24,26,27,31,32</sup>, providing an opportunity to predict the power of prospective 85 studies with larger sample sizes. However, relevant theory and methods have not yet been 86 87 developed.

88

In this study, we comprehensively assess the performance of GWFM analysis using a GBMM (Fig. 89 **1**). In comparison to state-of-the-art methods, we evaluate the calibration of PIP through 90 simulations with various genetic architecture settings. We then compare the performance of 91 identifying causal variants, with respect to mapping precision, credible set size, replication rate 92 93 of discovery in an independent sample, and out-of-sample prediction using fine-mapped variants. Moreover, we develop a LD-based method to construct local credible sets (LCSs), where a  $\alpha$ -LCS 94 represents a minimal set of SNPs in high LD that capture a causal variant with a posterior 95 probability of  $\alpha$ , and estimate the proportion of SNP-based heritability explained by LCSs. To 96 characterise the overall fine-mapping power in the current study, we propose a concept of global 97 credible sets (GCSs), with a  $\alpha$ -GCS representing a minimal set of genome-wide SNPs that capture 98 99  $\alpha$ % of all causal variants for the trait. Furthermore, leveraging the genetic architecture estimated from SBayesRC, we develop a method to predict the power of fine-mapping and variance 100 explained by the identified variants in prospective studies. With this method, we can estimate the 101 minimal sample size required for identifying a desired proportion of causal variants or those 102 variants explaining a desired proportion of the SNP-based heritability  $(h_{SNP}^2)$ . Finally, we apply 103

SBayesRC to the UK Biobank (UKB) data with 13 million SNPs to identify putative causal variants
 for 600 complex traits and diseases and compare the fine-mapping results using 48 well-powered
 traits from 6 categories.

107

#### 108 Results

### 109 Method overview

We selected SBayesRC as the GBMM for GWFM (Fig. 1), as it has been shown to outperform other 110 GBMMs in polygenic prediction<sup>27</sup>. SBayesRC is a hierarchical multi-component mixture model, 111 where LD between SNPs is better modelled by matrix factorisation and functional genomic 112 annotations are fitted jointly with the summary statistics in a unified computational framework 113 (Methods). To optimize its performance for fine-mapping, we implemented an algorithm to 114 automatically determine the number of mixture components in the model (Methods). In contrast 115 116 to the existing fine-mapping methods, we fit all SNPs simultaneously and employed MCMC sampling to obtain the joint posterior distribution of model parameters and PIPs 117 (Supplementary Table 1). In each MCMC iteration, we sampled a dummy variable for each SNP 118 to indicate whether the SNP had a nonzero effect, conditional on the effects of other SNPs. After 119 MCMC sampling, PIP was calculated as the frequency with which the SNP had nonzero effects 120 across the iterations (Methods). 121

122

123 A high PIP value provides evidence of a causal variant. However, a causal variant may not have a high PIP value if it is in strong LD with other SNPs. For example, if the causal variant is in perfect 124 125 LD with another SNP, then the PIP is expected to be 0.5 for each variant, regardless of the sample size. Therefore, the CS concept has been introduced to capture causal variants in strong LD with 126 non-causal SNPs<sup>9,33</sup>. It is common to consider CS for SNPs that are close in physical distance, such 127 as within a 100kb window<sup>34,35</sup>. However, we reason that this approach will miss causal variants 128 129 with SNPs in long-range LD, and therefore proposed a new method to construct LCS based on LD between SNPs (**Methods**). Starting from the SNP with the largest PIP, we aimed to construct a  $\alpha$ -130 LCS for each "free" SNP (SNP that has not been included in any LCSs), by first selecting other "free" 131 SNPs in high LD ( $r^2 > 0.5$ ) and then summing over their PIPs in a decreasing order until the sum 132 is at least  $\alpha$  (a common strategy used in the literature<sup>11,12</sup>). To avoid having too many SNPs with 133 small PIPs in the LCS, we calculated the posterior  $h_{SNP}^2$  enrichment probability (PEP), where PEP 134 is the probability that the focal LCS explains more  $h_{SNP}^2$  than a random set of SNPs with the same 135 size. The  $\alpha$ -LCS was eventually reported if its PEP was greater than 0.7. 136

137

138 In addition to LCS, we proposed another type of CS, GCS. Given the estimated number of causal 139 variants from GBMM ( $m_c$ ), a  $\alpha$ -GCS was computed as the cumulative sum of decreasingly ranked

140 PIPs that is greater than  $\alpha \times m_c$ . It can be shown that a  $\alpha$ -GCS is expected to cover  $\alpha$ % of all causal 141 variants for the trait (**Methods**), with the size of  $\alpha$ -GCS reflecting the power of identifying the 142 causal variants given the data (the higher the power, the smaller the  $\alpha$ -GCS size). Moreover, from 143 the MCMC samples of SNP effects, we estimated the proportion of  $h_{SNP}^2$  explained by the LCSs and 144 GCS (**Methods**).

145

Based on  $m_c$  and the distribution of causal effect sizes estimated from GBMM, we developed a 146 method to predict the power and the proportion of  $h_{SNP}^2$  explained by the fine-mapped variants, 147 given a sample size (Methods and Supplementary Note). This method allows us to estimate the 148 minimal sample size required to achieve a desired power of identifying all causal variants or 149 identifying the causal variants that explain a desired proportion of  $h_{SNP}^2$  of the trait, using the 150 ancestry-specific fine-mapping result. Our method to predict fine-mapping power is analytically 151 tractable and has been implemented in a publicly available online 152 tool (https://sbayes.pctgplots.cloud.edu.au/shiny/power/). 153

154

We compared SBayesRC to several state-of-the-art fine-mapping methods, including FINEMAP<sup>12</sup>,
SuSiE<sup>11</sup>, FINEMAP-inf<sup>13</sup>, SuSiE-inf<sup>7</sup>, and PolyFun+SuSiE<sup>19</sup>, as well as another GBMM, SBayesC (i.e.,
two-component SBayesR<sup>24</sup>). All these methods assume a point-normal mixture prior for the SNP
effects (Methods and Supplementary Table 1). A full list of acronyms used in this study can be
found in Supplementary Table 2.

160

# 161 Calibration of fine-mapping methods under various genetic architectures

We performed extensive genome-wide simulations to calibrate different fine-mapping methods 162 under various genetic architectures, using 100,000 individuals with  $\sim$ 1 million HapMap3 SNPs 163 from the UKB<sup>36</sup>. We started by simulating a sparse genetic architecture, where 1% SNPs were 164 randomly chosen as causal variants, with their effects sampled from a normal distribution, 165 contributing 50% of the phenotypic variance. In this simulation, the data-generative model is 166 167 consistent with the model used in SBayesC as well as the local fine-mapping methods in comparison. To challenge these methods, we simulated additional two complex genetic 168 architectures (**Methods**). One was a large-effects architecture, where 10 random causal variants 169 contributed 10% of the phenotypic variance and the remaining causal variants contributed 40%. 170 Another complex genetic architecture was based on the sparse architecture but allowed for 171 extensive LD between causal variants and SNP markers. This was achieved by sampling the causal 172 variants only from SNPs in the high LD and high minor allele frequency (MAF) group, and 173 174 therefore referred to as LD-and-MAF-stratified (LDMS) architecture. To calibrate each fine-

175 mapping method, we evaluated how well the reported PIPs are consistent with the actual fraction

- 176 of causal variants, i.e., the true discovery rate (TDR).
- 177

Results showed that overall, the GWFM methods had the best calibration, the enhanced region-178 specific methods with an infinitesimal effect (i.e., FINEMAP-inf and SuSiE-inf) the second, and the 179 standard region-specific methods (i.e., FINEMAP and SuSiE) the worst (Fig. 2). Under the sparse 180 181 genetic architecture, PIPs from SBayesRC/SBayesC were in strong concordance with the TDR across its full spectrum (Fig. 2a). The concordance was reasonably good for SuSiE-inf and 182 FINEMAP-inf, although with a trend of deflation in SNPs with low PIP, whereas for SuSiE and 183 FINEMAP, even in SNPs with high PIPs, a notable inflation was observed, indicating a lack of 184 control of FDR (=1-TDR) (Fig. 2b-c). When the large-effects or LDMS architecture was used, the 185 assumption in the point-normal BMM was violated in a way that the causal effects did not come 186 187 from a single normal distribution or that the causal variants were not randomly distributed across the genome. Consequently, PIPs from the point-normal BMM were no longer accurately 188 tracking the true probabilities of causality. When the LDMS architecture was used, the FDR was 189 even more poorly controlled in these methods (Fig. 2d-i). However, when SBayesRC was used, 190 with LD and MAF bins as annotations, the strong concordance between PIP and TDR held in 191 various architectures, although none of these architectures matched exactly with the analytic 192 193 model assumed in SBayesRC.

194

In conclusion, the region-specific fine-mapping methods tended to have inflated FDR when the
model assumptions were not met. In contrast, SBayesRC produced robust PIPs that were well
calibrated under various genetic architectures.

198

### 199 Local and global credible sets

200 In addition to individual SNP PIP, CS is another critical statistic in fine-mapping. Here, we assessed the performance of SBayesRC in identifying LCS and GCS. For each LD block, we 201 computed an  $\alpha$ -LCS that contains at least a causal variant with a probability of  $\alpha$  and is enriched 202 in  $h_{SNP}^2$  (PEP > 0.7). We first evaluated the true discovery rate for identifying LCS, defined as the 203 actual fraction of the LCS with at least a causal variant. The simulation result showed that the 204 SBayesRC has a similar TDR to SuSiE-inf, which had the best PIP calibration among the region-205 specific fine-mapping methods (**Fig. S1a-c**). However, SBayesRC was significantly more powerful 206 (Fig. 3a-c) and had a remarkably smaller LCS size than SuSiE-inf at the same  $\alpha$  threshold (Fig. 207

**3d-f**). For instance, when  $\alpha$ =0.9, SBayesRC outperformed SuSiE-inf by up to 221% improvement in power and 41% reduction in LCS size across the three genetic architectures.

210

The  $\alpha$ -GCS is expected to cover  $\alpha$  proportion of the causal variants across the genome (**Methods**). Under various simulation scenarios, our GCS accurately represented the true proportion of causal variants (**Fig. S2a-c**), in contrast to the significant deflation observed with SBayesC (**Fig. S2a-c**). Furthermore, we observe a good agreement between estimated and observed power at any given PIP threshold from SBayesRC (**Fig. S2d-f**). Additionally, SBayesRC gave an unbiased estimate for the proportion of  $h_{SNP}^2$  explained by the GCS SNPs, regardless of the given  $\alpha$  value, under various

217 scenarios (Fig. S2g-i).

218

# 219 Improved mapping precision for identifying causal variants

Our simulation results have shown that SBayesRC had the best calibration even under the 220 221 architecture that matched with the assumed model for the region-specific fine-mapping methods. We next quantified the mapping precision of these methods. The mapping precision was defined 222 223 as the distance of the identified variant that passed a given PIP threshold to the nearest causal variant. Hence, the smaller the distance, the higher the mapping precision, e.g., the distance is 224 zero if the causal variant itself is identified. Results from the sparse architecture simulation 225 showed that 97.8% of SBayesRC identified SNPs with PIP > 0.9 were the causal variants, and 99% 226 significant SNPs were located within 16.4kb distance to the causal variants (Fig. 4a). With the 227 same PIP threshold, 95.5% and 94.3% of SuSiE-inf and FINEMAP-inf identified SNPs were the 228 causal variants, slightly higher than that of 95.3% and 94.0% from SuSiE and FINEMAP, with 99% 229 significant SNPs located within 25.8kb (SuSiE-inf) and 31.3kb (FINEMAP-inf) to the causal 230 variants, compared to that of 32.7kb and 36.7kb for SuSiE and FINEMAP, respectively. In 231 conclusion, given a PIP threshold of 0.9, SBayesRC led to an at least 2% increase in TDR and a 64% 232 (16.4kb/25.8kb) reduction in the distance to the causal variants, both indicating improved 233 mapping precision compared to the existing methods. We also ran a LD block-wise SBayesC 234 235 analysis, with model parameters estimated from each region separately. Our result showed that the mapping precision remained notable higher than the competing region-specific fine-mapping 236 methods (Fig. S3). 237

238 239

240

241 242 In the simulation with large-effects architecture, the mapping precision for all methods decreased due to the decrease of average per-SNP heritability (from 0.5/10,000 to 0.4/9,990). However, SBayesRC still had the highest precision among all methods (**Fig. 4b**). In the simulation with LDMS architecture, SBayesRC demonstrated a substantially higher mapping precision than the

other methods (**Fig. 4c**), likely because SBayesRC allowed the model to weigh SNPs differentially

based on their LD and MAF property so that the causal variants were better identified.
Furthermore, we compared SBayesRC to Polyfun+SuSiE<sup>19</sup>, which is a stepwise method that
accounts for the effect size stratification (by LD and MAF annotations) through a prior estimated
from stratified LD score regression (S-LDSC)<sup>37,38</sup>. Indeed, Polyfun+SuSiE improved the mapping
precision compared to the region-specific methods, but was still significantly inferior to
SBayesRC (Fig. 4c). These simulation results suggested that SBayesRC is a reliable method for
GWFM and can substantially improve the mapping precision of identifying causal variants.

251

### 252 Improved replication rate of identification with less bias in estimation

In real data analysis, direct evaluation of mapping precision is not feasible, because which 253 variants have causal effects on a trait are often unknown. Alternatively, we can evaluate the 254 replication rate of the identified variants using an independent sample<sup>13</sup>. Here, we define the 255 256 replication rate as the proportion of variants with a significant PIP (e.g., PIP > 0.9) from the GWAS sample to be repeatedly identified in an independent (replication) sample with the same or a 257 smaller PIP threshold. It is expected that the method that identifies most causal variants from the 258 GWAS sample will have the highest replication rate, as the false positives are unlikely to be 259 replicated. 260

261

262 We performed simulations using the UKB samples of European ancestry and split samples into 263 independent datasets for discovery and replication. Putative causal variants were identified at the PIP threshold of 0.9 in the GWAS data (n=100,000). We then quantified the replication rate of 264 265 the putative causal variants at different significance thresholds in two replication datasets (n=100,000 and 200,000). Using SBayesRC, roughly 33% of identified SNPs can be replicated at 266 PIP > 0.9 when replication n = 100,000, and the replication rate increased to 71% when the 267 replication sample size was doubled (**Fig. 4d**). It may seem counter-intuitive that only a fraction 268 269 of SNPs was replicated despite using the same PIP threshold of 0.9 in both the discovery and replication datasets. This discrepancy is because there exists a sampling variation in the causal 270 variants identified from distinct samples. As expected, the replication rate increased when using 271 a lower threshold for replication, e.g., with PIP > 0.1, 79.6% of the identified SNPs can be 272 replicated when replication *n*=100,000. Compared to other methods, SBayesRC demonstrated 273 274 significantly higher replication rate at each of the PIP thresholds, while differences among the other four methods were small. We also quantified the replication rate in the reverse case where 275 the GWAS sample size was 200,000 but the replication sample size was only 100,000, to mimic 276 the reality that the sample size of replication data is often much smaller than that of discovery. In 277 this scenario, we found that 19% of the identified SNPs can be replicated at PIP > 0.9 using 278

SBayesRC, and the replication rate of SBayesRC remains significantly higher than that of other
methods at each PIP threshold (Fig. S4a).

281

We then assessed the replication rate in the UKB height by constructing different discovery and replication datasets as in the simulation. The results were consistent with the observations from the simulation study (**Fig. 4e** and **Fig. S4b**). Compared to the region-specific methods, SBayesRC improved the replication rate by 11.3% (compared to FINEMAP) and by 1.2% (compared to SuSiE-inf) at PIP > 0.9 when replication n=100,000, and improved the replication rate by 19% (compared to FINEMAP) and by 3.5% (compared to SuSiE-inf) when replication sample size was doubled.

289

Moreover, we examined the bias in effect size estimates of putative causal variants identified from fine-mapping, through regressing their marginal effect sizes estimated from the replication samples on the joint effect sizes estimated from the GWAS sample (the regression slope is expected to be one for an unbiased estimation). In the simulation and UKB height analyses, the regression slope from SBayesRC was 0.978 and 0.974, respectively, superior to all the other methods (**Fig. 4f-g**), likely due to the genetic architecture was estimated simultaneously in SBayesRC but was preset or estimated locally in other fine-mapping methods.

297

These analyses suggested that the identified SNPs from SBayesRC are more likely to be causal because of the relatively high replication rate in independent samples and the negligible bias in effect size estimation, compared to the other methods.

301

# 302 Improved prediction accuracy using fine-mapped variants

Another approach to evaluate the results of fine-mapping is to conduct an out-of-sample 303 304 prediction using the fine-mapped variants. Since all the Bayesian methods used in this study provide the posterior mean of SNP effects, we computed polygenic scores (PGS) based on the 305 identified variants from each of the methods and evaluated the prediction accuracy in a validation 306 sample. We split the 100K samples into 95K training samples to perform the fine-mapping 307 analysis using all these Bayesian methods and predicted the phenotype for 5K independent 308 309 individuals as validation samples. We found that overall, SBayesRC had a higher prediction accuracy compared to the other methods, outperforming them by at least  $\sim 17\%$  at a PIP 310 threshold of 0.9, with a relatively smaller number of SNPs included in the predictor (**Fig. 5a**). This 311 is consistent with the result that SBayesRC resulted in a lower FDR than the other methods (Fig. 312 313 2a).

We further compared the performance of these methods by trans-ancestry prediction in real 315 traits. Specifically, we used the fine-mapped variants and estimated posterior effect sizes 316 obtained from the UKB individuals of the European (EUR) ancestry to predict the phenotypes in 317 three other ancestries in UKB: African (AFR), East Asian (EAS) and South Asian (SAS). We selected 318 6 complex traits that had at least 50 identified SNPs at a PIP threshold of 0.9. We compared the 319 320 performance of trans-ancestry prediction between SBayesRC and SuSiE-inf, because SuSiE-inf has 321 exhibited a superior performance compared to the others. The result showed that compared to SuSiE-inf, SBayesRC improved the trans-ancestry prediction accuracy using fine-mapped variants, 322 with a nearly 10-fold increase in the mean relative prediction  $R^2 \left(\frac{R_{SBayesRC}^2 - R_{SuSiE-inf}^2}{R_{SuSiE-inf}^2}\right)$  across traits 323 and ancestries (Fig. 5b). We further compared the performance of SBayesRC and SuSiE-inf for 324 325 trans-ancestry prediction using the identified credible set SNPs. Similar to the comparison result 326 based on fine-mapped variants, SBayesRC improved the trans-ancestry prediction accuracy based on the SNPs in the 90-LCS (Fig. S5; 1.7-fold increase on average). Since it is parsimonious 327 to assume that the common causal variants and their effect sizes are mostly shared between 328 ancestries<sup>39,40</sup>, we expect to observe a strong concordance in prediction accuracy between EUR 329 and other ancestries using putative causal variants identified from the EUR sample with high 330 confidence. To investigate this, we quantified the transferability of fine-mapped SNPs by 331 computing the ratio of per-SNP prediction accuracy in a hold-out EUR sample to that in a different 332 ancestry. The result showed that on average this relative prediction accuracy of SNP increases 333 with its PIP calculated in the EUR GWAS sample (Fig. 5c). These results suggested that SBayesRC 334 has higher power of fine-mapping and higher accuracy of variant effect estimation. 335

336

#### 337 Prediction of fine-mapping power and variance explained

As a unique feature of the GWFM approach, the genetic architecture estimated from SBayesRC 338 provides information to predict the proportion of causal variants identified from fine-mapping 339 (power) and the proportion of  $h_{SNP}^2$  explained by these variants (PHE) for future studies 340 (Methods and Supplementary Note). To evaluate our approach, we computed the predicted 341 342 values of power and PHE at a spectrum of GWAS sample sizes and projected the outcome of finemapping using SBayesRC onto the prediction using data from the simulated trait with sparse 343 architecture, height<sup>36</sup>, high density lipoprotein (HDL), schizophrenia (SCZ)<sup>41</sup>, and Crohn's Disease 344 (CD)<sup>42</sup>. These traits were selected to represent different genetic architectures (Fig. 6a-c). Despite 345 some variations across traits, the outcomes from the fine-mapping analyses were overall 346 consistent with the theoretical predictions (Fig. 6d,e). While our theoretical prediction does not 347

model LD between SNPs, the extent to which the observed values were consistent with the
predicted suggests that LD had been effectively, albeit not perfectly, accounted for by our LCSs.

350

Take SCZ for example. Using the latest GWAS summary statistics from the psychiatric genomics 351 consortium dataset<sup>41</sup>, we identified 13 SNPs and 222 credible sets, collectively explaining 3.9% 352 of  $h_{SNP}^2$  at the liability scale<sup>43</sup>. These estimates are highly consistent with our theoretical 353 prediction given the 53,386 cases and 77,258 controls in their study<sup>41</sup>, which is equivalent to a 354 sample size of 228,810 on the liability scale (ref<sup>44</sup>; **Methods**). For a prospective study using 355 356 SBayesRC, we predict that ~180k cases would be required to fine-map 1,000 common causal variants (estimated to be 1.2% of all common causal variants), assuming an equal number of 357 controls and a population prevalence of 0.01 (Methods), collectively accounting for about 20% 358 of  $h_{SNP}^2$  (Fig. 6). With ~550k cases under the same assumption, we will be able to identify 10% 359 causal variants explaining 50% of  $h_{SNP}^2$  in SCZ. To fine-map variants accounting for 80% of  $h_{SNP}^2$ , 360 it was estimated to require 1.4 million cases. 361

362

## 363 Genome-wide fine-mapping in complex traits from UK Biobank

We applied GWFM with SBayesRC to 600 complex traits (598 from the UKB) and developed an 364 online resource to query these fine-mapping results (see URLs; Supplementary Table 3). We 365 selected these 598 UKB traits based on z-score > 4 and high confidence for heritability estimates 366 using LD score regression (https://zenodo.org/records/7186871). To better capture the causal 367 variants, we used 13 million imputed SNPs with functional genomic annotations from Finucane 368 et al.<sup>37</sup>. Here, we focus on discussing the results for 48 complex traits that had sufficient power, 369 including SCZ, CD<sup>41,42</sup> and 46 UKB traits measured in the European ancestry inferred individuals 370 (Methods). At the PIP significance threshold of 0.9, we identified 2,868 SNPs associated with 48 371 complex traits, 1,641 of which were not identified by LD clumping, and 22,803 0.9-LCSs with an 372 average size of 8.7 SNPs. On average across these 48 traits, we estimated that although these fine-373 mapped variants and LCSs only captured 0.75% of the causal variants, they accounted for 17.4% 374 of the  $h_{SNP}^2$ . 375

376

Given the estimated genetic architecture for these 48 traits, we applied our theoretical prediction approach to predict the power of prospective GWAS studies. With a GWAS sample size of 2 million individuals, we predict that the average power is 9.5% (**Fig. 7a**) and average PHE is 54.1% (**Fig. 7b**). The predicted values varied substantially between trait groups. Blood cell traits had both the highest power (29.7%) and highest expected proportion of  $h_{SNP}^2$  explained (86.9%), while cognitive traits have the smallest power (16.9%) and smallest expected proportion of genetic variance explained (63.1%). To achieve a PHE of 50%, blood cell traits require a GWAS sample

size of only 1 million individuals, while cognitive traits necessitate a sample size of 5 million individuals, due to the differences in genetic architecture across complex traits. The required sample size increased to 3 million and 10 million for blood cell counts and cognitive traits, respectively, to achieve a PHE of 80% (Fig. 7b).

388

The global credible set  $\alpha$ -GCS varied in the credible set size and PHE estimate across traits (**Fig.** 389 7c). On average, the 0.1-GCS, i.e., covering 10% of causal variants, consisted of 1% of the genome-390 wide SNPs, which explained 31.8% of the  $h_{SNP}^2$  (Fig. 7d). Among the analysed complex traits, 391 diseases had the largest GCS sets, requiring 1.9% genome-wide common SNPs to cover 10% 392 common causal variants. In contrast, blood cell traits had the smallest GCS, requiring merely 0.21% 393 genome-wide common SNPs to cover 10% common causal variants. Interestingly, the 0.1-GCS for 394 blood cell traits explained 44.3% of the total genetic variance, compared to 20.8% explained by 395 the GCS for cognitive traits, highlighting the less polygenic genetic architecture of blood cell traits. 396

397

Over the 48 complex traits, the number of fine-mapped variants from SBayesRC was highly 398 correlated with the number of identified GWAS loci (Fig. S6), ranging from 1 to 489, with an 399 400 average of 86.2 across complex traits (Fig. S7). Compared to the genome-wide SNPs and GWAS identified SNPs after LD clumping, the 2,868 putative causal variants had a significant 401 overrepresentation in functional genomic regions included in the functional genomic 402 annotations<sup>37</sup>, such as coding, promoter, and enhancer regions, and were significantly depleted 403 in repressed regions (Fig. 8a), suggesting the importance of functional annotations. Of these 404 variants, 651 (22.8%) were in association with more than one complex trait, highlighting the 405 prevalence of pleiotropy in human genome. Moreover, the number of traits that the variant had 406 pleiotropic effects decreased with its minor allele frequency (Fig. S8), consistent with that highly 407 pleiotropic variants would be expected to be removed from the population or kept at low 408 frequencies due to natural selection<sup>45</sup>. 409

410

# 411 Functional annotations helped pinpoint the putative causal variants

One notable example is a variant (rs1421085) at the FTO locus, which was identified to be a 412 putative causal variant using SBayesRC for body mass index (BMI), body fat percentage (BFP), 413 414 hip circumference (HC) and waist circumference (WC). It has been previously validated that this variant plays a causal role in adipocyte thermogenesis regulation<sup>46</sup>. Unlike the results from the 415 standard GWAS where many SNPs in the FTO locus exhibited a signal at genome-wide significance 416 level, our analysis showed that only the known causal variant (rs1421085) was significantly (PIP > 417 418 0.9) associated with BMI (Fig. 8b). In contrast, applying other methods (SBayesR and SuSiE-inf) without functional annotations to the locus identified the GWAS lead SNP instead, underscoring 419

420 the importance of incorporating functional annotations. In particular, the annotations of 421 conservation across species, especially primates, helped distinguish the causal variant from the GWAS lead SNP (Fig. 8c). Moreover, a secondary signal rs76488452 (PIP=0.85) was identified by 422 SBayesRC, which has not been previously reported but was included in a local credible set of 5 423 SNPs in both SBayesR and SuSiE-inf (Fig. S9). We found this SNP resided in a conserved region in 424 primates and was also significant in the COJO analysis (p-value =  $1.8 \times 10^{-17}$ ) conditional on the 425 426 known causal variant. Notably, the secondary signal (rs76488452) was only nominally significantly in the GWAS marginal analysis (p-value =  $3.6 \times 10^{-4}$ ), whose trait-increasing allele was 427 in negative LD (r=-0.16) with that of the known causal variant, indicating that this SNP is likely to 428 have a masked effect<sup>47</sup> (estimated masked effect size  $b_2 - r * b_1 = 0.02$ , consistent with the reported 429 430 GWAS marginal effect size).

431

432 Another example is from the fine-mapping results for SCZ. We identified 13 SNPs at PIP > 0.9 for SCZ from the latest meta-analysis, 5 of which were the same SNPs that were identified using 433 FINEMAP in their study<sup>41</sup>, and all the 8 SNPs identified by FINEMAP were included in our 0.9-434 LCSs. We recapitulated a missense variant (rs13107325) in *SLC39A8*, a gene highlighted in the 435 latest SCZ analysis for its function in regulating dendritic spine density<sup>48,49</sup>. Furthermore, we 436 identified a secondary variant at the same locus, located in important functional regions (Fig. 8d-437 e). Among the 5 novel fine-mapped SNPs that were not identified by FINEMAP with individual 438 439 PIP, 3 were missense variants (Fig. S10a-c). We highlight rs11845184, which is located within SECISBP2L (Fig. S10a). SECISBP2L is highly expressed in brain-related tissues (Fig. S11), 440 specifically in differentiating oligodendrocytes, where the SECISBP2L-DIO2-T3 pathway 441 mediates the autonomous regulation of oligodendrocyte differentiation during myelin 442 development<sup>50</sup>. Moreover, we identified novel putative causal variants for CD (**Supplementary** 443 Table 4). Using SBayesRC, we fine-mapped 31 variants, of which 10 were missense variants, and 444 445 all 3 variants identified in the previous study using the same data were recapitulated<sup>42</sup>. In addition, compared to a recent exome-wide association study for CD<sup>51</sup>, we identified 4 novel 446 genes (LACC1, SLAMF8, MAN2B2 and GPR35) with missense putative causal variants (Fig. S12). 447 These results demonstrated the power of SBayesRC for identifying the plausible causal variants 448 and provide a valuable resource for downstream analysis and functional validation. 449

450

### 451 Discussion

In this study, we comprehensively evaluated the performance of GWFM using SBayesRC by extensive simulation and real data analyses, compared with the existing fine-mapping methods that consider one genomic region at a time. Our results showed that both PIP and CS from SBayesRC were correctly calibrated under various genetic architectures, indicating well

controlled FDR. In contrast, the other methods produced mis-calibrated PIP and CS with inflated 456 FDR, when the genetic architecture did not match the model assumption. While all fine-mapping 457 methods gave a higher mapping precision than that from GWAS<sup>7</sup>, SBayesRC had the highest 458 precision across genetic architecture scenarios. Furthermore, in both simulation and real trait 459 analyses, SBayesRC showed significantly higher replication rate and prediction accuracy but less 460 estimation bias in an independent sample using fine-mapped SNPs, compared with the other 461 methods. In the real data analysis, we showed examples where SBayesRC pinpointed the putative 462 causal variants that were missed by the other methods. All of these results indicate that SBayesRC, 463 as a method for GWFM analysis, remarkably improves the identification of causal variants. 464

465

We proposed a new LD-based method to compute LCSs and estimate their contribution to the 466 SNP-based heritability. This method overcomes the limitation of existing window-based 467 468 approaches that causal variants with SNPs in long-range LD would not be captured. In addition to LCSs, SBayesRC allows us to compute a GCS for the trait, which informed the power of 469 identifying the causal variants and the  $h_{SNP}^2$  explained by the identified SNPs given the data. This 470 computation requires an unbiased estimation on the total number of the causal variants, which 471 can only be done when analysing all SNPs jointly in the model. The analysis of 48 complex traits 472 473 showed that although as many as 22,803 variants or LCS were identified, they only captured 0.75% of all common causal variants and contributed 17.4% genetic variance, suggesting many causal 474 variants with very small effects are yet to be discovered (Fig. 7c,d). 475

476

477 We have provided a theoretical prediction of fine-mapping power given a sample size and the estimated genetic architecture (Supplementary Note). This is useful to inform the experimental 478 479 design of future fine-mapping studies regarding the sample size required to identify a certain number of causal variants or those explaining a certain proportion of  $h_{SNP}^2$ . The robustness of our 480 prediction approach is supported by projecting the outcomes of real data analyses to the 481 landscape of predicted values. For height, based on the UKB data (n = 350k), we predicted that 482 when the sample size increases to 5 million, the number of fine-mapping discoveries would be 483 ~10,000 considering significant PIPs only or ~30,000 considering both significant PIPs and LCSs, 484 485 explaining up to 95% of the genetic variance (**Fig. 6**). This prediction is consistent with the finding of a recent GWAS with 5 million individuals, which reported 12,111 independently significant 486 SNPs identified from COJO accounting for nearly all of the common SNP-based heritability in 487 height<sup>40</sup>. 488

489

While the concept of credible set has evolved over time<sup>11,12,52</sup>, it is still common to focus on
individual SNP PIP in the downstream analysis, probably because the CS include too many SNPs

492 to follow up. Our study provided important implications regarding this issue. First, CS may miss 493 the true causal variant if not all possible causal variants are fitted in the model, underscoring the importance of considering all common SNPs in the fine-mapping analysis. Second, our GWFM 494 approach can reduce the credible size, as shown in both simulation and real trait analysis (only 495  $\sim$ 8.7 SNPs per credible set), facilitating the consideration of CS in practice. Third, in the presence 496 497 of complete LD between SNPs and the causal variants, the PIP of a causal variant may never be significant regardless of sample size, but leveraging functional genomic annotations may help 498 distinguish causal from non-causal variants. In this sense, genomic annotations play a greater role 499 than the increase of GWAS sample size. 500

501

The advantages of SBayesRC over the region-specific fine-mapping methods arise from the 502 following aspects. First, SBayesRC involves a genome-wide analysis fitting all SNPs jointly. 503 504 Compared to the region-specific analysis, genome-wide analysis accounts for long-range LD and utilises all SNPs to estimate the genetic architecture, thereby improving fine-mapping. Of note, 505 even when the same LD blocks are used in both types of analyses, the latter is still superior 506 because of the better estimation of genetic architecture parameters from genome-wide SNPs. 507 Second, SBayesRC assumes a more realistic distribution of SNP effects through using MAF/LD 508 groups along with other functional annotations. In addition, the impact of annotations on the SNP 509 510 effect distribution is estimated within the same model, fostering a formal Bayesian learning 511 process. The existing fine-mapping methods, however, either do not leverage annotation data or lack a unified framework for the joint analysis with GWAS data. Third, SBayesRC utilises MCMC 512 513 sampling to estimate model parameters and PIPs, which is asymptotically exact. Both FINEMAP and FINEMAP-inf use shotgun stochastic search, while both SuSiE and SuSiE-inf use variational 514 Bayes to compute the Bayes factors for the causal models and therefore the PIPs. It has been 515 previously shown that MCMC sampling generally leads to a higher accuracy of capturing the 516 posterior distribution than the other approximation approaches<sup>30</sup>. To further justify our choice 517 of SBayesRC as the method for GWFM, we ran SBayesRC within each block separately and 518 quantified the mapping precision. We found that the mapping precision decreased compared to 519 the genome-wide SBayesRC but remained higher than the other methods (**Fig. S2**). For example, 520 99% of SNPs identified by the region-specific SBayesRC were located within 23.1Kb to causal 521 522 variants, compared to the number of 16.4Kb for the genome-wide SBayesRC and 25.8Kb for SuSiE-inf. 523

524

525 We note several limitations of this work. First, there are certainly more complicated scenarios 526 about effect size distribution for causal variants that have not been investigated in our 527 simulations. However, to our knowledge, SBayesRC is one of the most flexible models to

accommodate various scenarios because it assumes a multi-component Gaussian mixture, and 528 529 we have further allowed the method to automatically choose the number of mixture components. Second, unlike an individual-level model where each PIP is calculated conditional on the effects 530 from all other SNPs jointly, SBayesRC is a summary-level model where LD between LD blocks is 531 ignored so that SNPs beyond the region contribute to the PIP only through the mixture 532 distribution of SNP effects. Third, we only applied our method to the GWAS summary data from 533 534 relatively homogenous populations (inferred European ancestry) and the robustness of the methods on GWAS data based on trans-ancestry meta-analyses is not investigated. Fourth, 535 SBayesRC requires the LD information estimated from a cohort that matches with GWAS ancestry 536 without substantial sampling variation. Fifth, to create the credible set, a threshold of 0.5 was 537 arbitrarily chosen to define a set of SNPs in high LD. Latest methodological advancements in 538 Bayesian hypothesis tests based on hierarchical clustering can be used to relax this condition<sup>53</sup>. 539 540 Sixth, the prediction of mapping power is based on the genetic architecture estimates given a SNP set. However, the SNP set may change with the sample size (e.g., more common SNPs to be 541 observed in a larger sample size), which may affect the polygenicity and SNP-based heritability. 542 Despite these limitations, our study provides a robust and versatile GWFM framework for 543 identifying causal variants, highlighting the advantages of this approach over existing region-544 specific fine-mapping methods. With its capacity to enhance mapping power in the current study 545 546 and to predict mapping power for future studies, we believe GWFM using a state-of-the-art GBMM 547 will become the preferred method for analysing complex traits.

#### **Methods** 548 Low-rank GBMM 549 We used state-of-the-art GBMM that employed a low-rank model to improve computational 550 efficiency and robustness<sup>27</sup>. As described below, the low-rank GBMM can be derived from the 551 552 individual-level model. Consider a multiple linear regression of phenotypes on genotypes: $y = X\beta + e$ (1) 553 where **y** is an $n \times 1$ vector of complex trait phenotypes and **X** is an $n \times m$ matrix of mean-centred 554 genotypes, $\beta$ is $m \times 1$ vector of SNP effects on the trait, and **e** is $n \times 1$ vector of residuals with 555 $var(\mathbf{e}) = \mathbf{I}\sigma_e^2$ . Let 556 $\mathbf{K} = \mathbf{\Lambda}^{-\frac{1}{2}} \mathbf{U}' \mathbf{X}' n^{-1}$ (2)557 where $\Lambda$ and U are diagonal matrix of eigenvalues and matrix of eigenvectors for the LD 558 correlation matrix $\mathbf{R} = \mathbf{X}'\mathbf{X}/n$ , respectively. It follows that $\mathbf{K}'\mathbf{K} = \mathbf{P}n^{-1}$ , where **P** is the projection 559 matrix of **y** on the column space of **X**, and $\mathbf{K}\mathbf{K}' = \mathbf{I}n^{-1}$ . Multiplying both sides of Eq (2) by **K** gives 560 $Ky = KX\beta + Ke$ 561 (3) 562 or $\mathbf{w} = \mathbf{Q}\mathbf{\beta} + \mathbf{\epsilon}$ (4) 563 When only the top *q* principal components of **R** are used, the dimension of **w** is $q \times 1$ and **Q** is 564 $q \times m$ . Since $q \ll n$ , this model would have a substantially lower rank than Eq (1), improving the 565 computational efficiency for the estimation of **\beta**. With a recognition of **\mathbf{b} = \mathbf{X}' \mathbf{y}/n** is the GWAS 566 marginal effect estimates, w can be directly computed from the GWAS summary statistics. In 567 practice, we compute w and Q within quasi-independent LD blocks in the human genome. With 568 569 this low-rank model, we can estimate $\beta$ for all common variants jointly through considering $\beta$ as 570 random effects. In addition, this model allows a direction estimation of the residual variance, as $var(\epsilon) = I\sigma_e^2 n^{-1}$ , which can be used as a nuisance parameter to accommodate heterogeneity in 571 the summary statistics and LD reference<sup>27</sup>. 572 573 SBayesC and SBayesRC 574 GBMMs are flexible in the specification of the prior distribution of SNP effects. In SBayesC, the 575 prior for the effect size of variant *j* is,

577

576

#### $\beta_j \sim N(0, \sigma_\beta^2)\pi + \phi(1-\pi)$ (5)

where  $\sigma_{\beta}^2$  is the common variance across all the causal variants,  $\pi$  is the proportion of SNPs with 578 nonzero effects, and  $\phi$  is a point mass at zero. Both  $\sigma_{\beta}^2$  and  $\pi$  are considered as unknown, with a 579 580 scaled inverse chi-squared prior distribution and a uniform prior distribution, respectively<sup>27</sup>. 581

SBayesRC<sup>27</sup> is an extension of SBayesR<sup>24</sup>, which allows for a more realistic prior distribution of 582 SNP effects by assuming a multiple component mixture distribution 583

584

$$\beta_j \sim \sum_{k=1}^5 \pi_k N(0, \gamma_k \sigma_g^2) \tag{6}$$

where  $\boldsymbol{\gamma} = (\gamma_1, \gamma_2, \gamma_3, \gamma_4, \gamma_5)' = (0, 1 \times 10^{-5}, 1 \times 10^{-4}, 1 \times 10^{-3}, 1 \times 10^{-2})'$  are the prespecified coefficients to constrain the variance in each effect size distribution with respect to the total genetic variance  $(\sigma_g^2)$ , and  $\pi_k$  is the prior probability for the SNP effect belong to the *k*th distribution. To further account for the stratification of causal variants and their effects regarding functional annotations, SBayesRC assumes a SNP-specific prior probability of distribution membership,  $\pi_{jk}$ , depending on the annotations at each SNP, through a generalised linear model. Specifically,

592

$$f(\pi_{jk}) = \mu_k + \sum_{l=1}^c A_{jl} \alpha_{kl}$$

$$\tag{7}$$

where  $f(\cdot)$  is the probit link function,  $\mu_k$  is the intercept,  $A_{jl}$  is the value of annotation l on SNP j(either binary or continuous annotations), and  $\alpha_{kl}$  is the effect of annotation l on the prior probability of the SNP effect belonging to the kth distribution. Details of the method can be found in ref<sup>27</sup>.

597

### 598 Calculation of PIP

We assessed the strength of joint association of each SNP using the posterior inclusion probability (PIP), i.e., the probability of a SNP being included with a nonzero effect in the model, given the data. Let  $\delta_j$  be the indicator variable for the distribution membership for SNP *j*, with  $\delta_j = 1$ indicating a null effect and  $\delta_j = 2, ..., K$  indicating a nonnull component. We computed PIP for SNP *j* as

$$PIP_{j} = 1 - Pr(\delta_{j} = 1 | y) = 1 - \frac{f(y|\delta_{j}=1)\pi_{1}}{\sum_{k=1}^{J} f(y|\delta_{j}=k)\pi_{k}}$$
(8)

- 605 The likelihood function when  $\delta_i = 1$  are
- 606

$$f(y|\delta_j = 1) \propto \exp\left\{-\frac{y'_c y_c}{2\sigma_e^2}\right\}$$
(9)

where  $y_c$  is the adjusted y for all other effects except that for SNP *j*.

- 608 The likelihood function when  $\delta_i = k$  is
- 609

$$f(y|\delta_j = k) \propto \exp\{-\frac{y_c' y_c}{2\sigma_e^2}\}\lambda_k^{\frac{1}{2}} C_k^{-\frac{1}{2}} \exp\{\frac{r^2}{2C_k}\}$$
(10)

610 where  $\lambda_k = \frac{\sigma_e^2}{\gamma_k \sigma_g^2}$ ,  $C_k = n + \lambda_k$ ,  $r = X' y_c = X' e + n\beta$ . A full derivation of equation above can be 611 found in the supplementary Note.

612

For all GBMM analyses in this study, we ran Markov chain Monte Carlo (MCMC) sampling for 10,000 iterations with the first 2,000 samples as burn-in and we used the posterior mean over 8,000 posterior samples to estimate  $\pi$  and PIPs.

#### 617 Automatic determination of mixture components

The standard SBayesRC requires specification of the number of mixture components before the 618 analysis. It has been shown that the performance of polygenic prediction is robust to the number 619 of mixture components<sup>27</sup>. However, this may be a problem for fine-mapping if a small effect 620 component is unnecessarily included, where null SNPs are fitted by chance to explain negligible 621 622 variance. This is because these SNPs may affect the distribution of PIPs and cause a bias in the estimation of the number of causal variants. In this study, we have allowed the method to 623 automatically determine the number of mixture components for SBayesRC. The procedure 624 started with running SBayesRC using the default setting of five mixture components. After 500 625 iterations of MCMC, the smallest component would be removed if the genetic variance explained 626 by the SNPs in this component were less than half of that in the second smallest component. This 627 628 procedure was repeated until no component was removed from the model. The rationale is that 629 in most complex traits, due to the action of negative selection, most variation is attributed to variants with small effects<sup>31,32,54</sup>. Hence, if the smallest component is capturing true genetic effects, 630 it should contribute to a significant proportion of variance, unlikely to be substantially lower than 631 the second smallest component. 632

633

#### 634 Local and global credible sets

Similar to prior work<sup>14</sup>, we defined the local credible set SNPs as the minimum set of SNPs that 635 contains at least one causal variant with a probability of  $\alpha$ . To identify the  $\alpha$ -LCS, we ranked SNPs 636 based on their PIPs and constructed candidate credible set for each "free" SNP which was not in 637 any LCSs. For the focal SNP, the candidate credible set was created by including "free" SNPs in 638 639 high LD ( $r^2 > 0.5$ ) with a focal SNP and computed the  $\alpha$ -LCS by summing over PIPs in a decreasing order until the sum is at least  $\alpha$ . This process was iteratively repeated until all SNPs were 640 exhausted. For each  $\alpha$ -LCS, we calculated an LCS posterior SNP-heritability enrichment 641 probability, where PEP is the probability that the focal LCS explains more  $h_{SNP}^2$  than a random set 642 of SNPs with the same size. We reported all the 0.9-LCS with PEP > 0.7 for each LD block. The true 643 discovery rate was quantified as the proportion of identified  $\alpha$ -LCS containing at least one causal 644 variant, and the power was calculated as the proportion of simulated causal variants included in 645 the identified  $\alpha$ -LCS. 646

647

Analogous to the LCS, which identifies a set of SNPs that capture a causal variant with a probability of  $\alpha$ , the GCS identifies a set of SNPs that capture all causal variant with a probability of  $\alpha$ , which is equivalent to finding a set of SNPs that capture  $\alpha$ % of the causal variants. We computed the  $\alpha$ -GCS as the cumulative sum of decreasingly ranked PIPs that was greater than  $\alpha \times m_c$ , where  $m_c$  was the estimated number of causal variants from GBMM for the trait. The  $\alpha$ -

GCS is expected to cover  $\alpha$ % of all causal variants for the trait, i.e., the power of identifying the

654 causal variants given the data (**Supplementary Note**).

655

# 656 Estimation of power and variance explained given the data

- 657 For the identified SNPs using individual PIP or credible set, we estimated the power of identifying
- the causal variants given the data at a given threshold  $\alpha$ ,
  - $TPR_{\alpha} = \frac{\sum_{j} [PIP_{j}| PIP_{j} \ge \alpha]}{M\pi}$ (11)

660 A formal derivation is given in the **Supplementary Note**.

661

659

Moreover, we estimated the proportion of SNP-based heritability explained (PHE) by LCSs. Specifically, we computed PHE for a focal set (*i*) of SNPs in each MCMC iteration using the sampled values of SNP effects,

665 
$$PHE_{mcmc_{r},i} = \frac{\sum_{j} \left[\beta_{mcmc_{r},j}^{2} \mid j \in i\right]}{\sum_{m=1}^{M} \left[\beta_{mcmc_{r},m}^{2}\right]}$$
(12)

where  $β_{mcmc_r,j}$  is the sampled effect for SNP *j* from MCMC iteration *r* in the scaled genotype unit. Finally, we computed the posterior mean across MCMC iterations as the estimate for PHE<sub>*i*</sub>,

 $PHE_i = \frac{\sum_r PHE_{mcmcr,i}}{L}$ 

669 where L is the total number of MCMC iterations.

670

684

668

## 671 Prediction of power and variance explained for prospective studies

We aim to predict the power of identifying a certain proportion of the causal variants in a prospective fine-mapping analysis, given a sample size (n) and the genetic architecture of the trait, when PIP from a GBMM is used as the test statistic. As shown in the **Supplementary Note**, assuming that variance explained by the causal variant is *v*, the sampling distribution of PIP from the multi-component mixture model, e.g., SBayesRC, is

677 
$$PIP = 1 - \frac{1}{1 + \sum_{k=2}^{5} A_k \exp\{B_k Z\}}$$
(14)

678 where  $A_k = \frac{\pi_k}{\pi_1} \lambda_k^{\frac{1}{2}} C_k^{-\frac{1}{2}}$  and  $B_k = \frac{n\sigma_e^2}{2C_k}$  are two constants given the genetic architecture parameters 679 ( $\pi$  and  $h_{SNP}^2$ ), with  $\lambda_k = \frac{\sigma_e^2}{\gamma_k \sigma_q^2}$  and  $C_k = n + \lambda_k$ , and Z is a data-dependent random variable

680 following a non-central Chi-square distribution with the non-centrality parameter  $NCP = \frac{nv}{\sigma_e^2}$ : 681  $Z \sim \chi_1^2 (\frac{nv}{\sigma^2})$  (15)

682 Given the threshold of PIP being  $\alpha$  for the hypothesis test, the power to detect this causal variant 683 can be calculated as

$$Power_{v} = \Pr(PIP > \alpha | v) = \int_{\alpha}^{1} f(PIP | v) dPIP$$
(16)

(13)

where f(PIP|v) is Eq (14) above. To compute the power for identifying any causal variant, we 685 integrated out v by 686  $Power = \int_{\alpha}^{1} \int_{0}^{\infty} f(PIP|v)f(v) dv dPIP$ (17)687 where 688  $f(v) = f_{\beta}(v^{\frac{1}{2}})v^{-\frac{1}{2}}$ (18)689 and  $f_{\beta}(\cdot)$  is the distribution of  $\beta$  estimated from the SBayesRC model. 690 691 Therefore, given a sample size, the expected number of causal variants identified from fine-692 mapping is 693  $E[NCV] = m(1 - \pi_1) \times Power$ (19)694 The expected proportion of genetic variance explained by the fine-mapped variants is 695  $E[PHE] = m(1 - \pi_1)\sigma_g^{-2} \int_0^\infty Power_v \times vf(v) dv$ (20)696 Since it is computationally challenging to obtain an analytical solution, we opted to estimate these 697 quantities through Monte Carlo simulation (Supplementary Note). 698 699

#### 700 Disease sample size at the liability scale

For diseases or binary traits, we converted the GWAS summary statistics from the linear mixed model to the liability scale prior to running GBMM. Based on the method in Yang et al.<sup>44</sup>, we estimated the sample size at the liability scale that gives an equivalent power to detect a locus affecting a quantitative trait with the same properties,

705

$$N_{eq} = \frac{i^2 \nu (1 - \nu) N_{01}}{(1 - K)^2} \tag{21}$$

where *K* is the disease prevalence, v is the sample prevalence, i = h/K with *h* being the height of standard normal curve at the truncation point t = 1 - K, and  $N_{01}$  is the total number of cases and controls. Given the z-score ( $z_j$ ) from the original GWAS summary data for SNP *j*, the marginal effect and its standard error at the liability scale can be estimated as following ref<sup>55</sup>

$$SE_{j} = \sqrt{\frac{1}{2p_{j}(1-p_{j})(N_{eq}+z_{j}^{2})}}$$
(22)

711

710

$$b_j = z_j \times SE_j \tag{23}$$

712 where  $p_i$  is the minor allele frequency of the SNP.

713

The results from GBMM using the converted summary statistics will be directly comparable across traits regardless of the sample prevalence and the type of traits. In our prediction analysis of power, we compared results between diseases and quantitative traits based on the equivalent sample size estimated from Eq (23). Similarly, to estimate the number of cases required, in a casecontrol study with equivalent number of controls, to achieve a certain power, we rearranged the

719 same equation so that

720

$$N_{cases} = \frac{1}{2} \frac{(1-K)^2 N_{eq}}{i^2 \nu (1-\nu)}$$
(24)

721

## 722 Simulations based on imputed genotype data from the UK Biobank

To evaluate the performance of GBMM, we ran simulations using the imputed genotype data from the UK Biobank after quality controls (QC). In this study, we selected 300,000 unrelated individuals and included ~1.2 million HapMap3 SNPs with MAF > 0.01, Hardy-Weinberg equilibrium test  $P > 1 \times 10^{-6}$ , genotyping rate > 0.95, and imputation information score > 0.8 for simulations.

728

We randomly sampled  $m_c = 10,000$  casual variants from the genome for 100,000 individuals and simulated complex trait phenotypes based on the following model:

731

 $y = X\beta + e \tag{25}$ 

where **X** is the genotype matrix for the causal variants,  $\beta_i \sim N(0, h^2/m_c)$  and  $e_i \sim N(0, var(\mathbf{X}\boldsymbol{\beta})/m_c)$ 732  $(1/h^2 - 1))$  with  $h^2 = 0.5$  being the proportion of phenotypic variance explained by all the 733 causal variants. To check the robustness of GBMM, we also ran simulations under various settings. 734 735 For simulations under LD-MAF stratification model, we partitioned all the genome-wide SNPs into four LD and MAF groups (by their median values) and only sampled the 10,000 causal 736 variants in the high LD and high MAF group. For the major gene model simulation, we separated 737 the sampling of effect size for causal variants from two distributions, i.e., 10 random SNPs with 738 effects from  $N(0, 0.2 * h^2/10)$  and the rest SNPs with effects from  $N(0, 0.8 * h^2/9990)$ . 739

740

We ran a standard GWAS using the genotypes with the simulated phenotypes under different 741 settings. We then used the GWAS summary data to perform GBMM (SBayesRC<sup>27</sup> and SBayesC<sup>24</sup>) 742 implemented in GCTB, SuSiE<sup>11</sup>, FINEMAP<sup>12</sup>, SuSiE-inf<sup>13</sup>, FINEMAP-inf<sup>13</sup> and PolyFun-S<sup>19</sup> to detect 743 fine-mapped variants and compute corresponding PIPs and effect sizes. We used imputed 744 genotypes from 10,000 random samples from UK Biobank as the LD reference in this study. We 745 repeated the whole process 100 times and then quantified the true discovery rate, mapping 746 precision and replication rate for each method. The mapping precision was computed as the 747 physical distance between the identified SNPs and nearest causal variants. 748

749

### 750 Real data analysis

We analysed 598 UK Biobank complex traits GWAS summary data from Neale's lab (Data Availability) and the schizophrenia<sup>41</sup> and Crohn's disease<sup>42</sup> GWAS summary data. We selected these 598 traits with z-score > 4 and high confidence for heritability estimates using LD score

regression. We used the annotations from baseline model BaseLineLD v2.2<sup>38</sup> and extract the imputed SNPs with MAF > 0.001 and that are in common with the annotations, leading to 13,065,104 imputed SNPs passed the quality control. We used 10,000 random samples from the UK Biobank as the LD reference to run the SBayesRC and other region-specific fine-mapping analysis. We further extracted 48 well-powered traits with relatively large sample size (n > 100, 000), high heritability ( $h^2 > 0.1$ ) and at least a fine-mapped SNP at PIP > 0.9.

760

For the polygenic score prediction analysis using fine-mapped variants only, we performed 761 quality control for the imputed genotype data provided by the UKB analysis team<sup>36</sup>. We kept SNPs 762 with MAF > 0.01, Hardy-Weinberg Equilibrium test P >  $10^{-10}$ , imputation info score > 0.6 within 763 each ancestry samples. We removed samples with mismatched sex information, samples 764 withdrawn from participation and cryptic related samples following ref<sup>27</sup>. We separate the final 765 766 UKB dataset into 4 ancestries, European (EUR, N= 347,800), East Asian (EAS, N=2,252), South Asian (SAS, N=9,436) and African (AFR, N=7,006). The phenotypes with continuous values were 767 filtered within the range of mean +/- 7SD and then rank-based inverse-normal transformed 768 within each ancestry and sex group. The GWAS were performed using PLINK2 software<sup>5</sup> with sex, 769 age and first 10 principal component as covariates. Linear regression was used for continuous 770 traits and logistic regression for binary traits. 771

772

### 773 Supplementary Information

Supplementary data include 12 supplementary figures, 4 supplementary table and asupplementary note.

776

### 777 Data Availability

Our SBayesRC-enabled genome-wide fine-mapping results for 600 complex traits are available at 778 779 link (https://sbayes.pctgplots.cloud.edu.au/data/SBayesRC/share/Finemap/v1.0/). The UK formal application 780 Biobank data are available through to the UK Biobank (http://www.ukbiobank.ac.uk). The GWAS summary data for 598 complex traits in UK Biobank 781 are from http://www.nealelab.is/uk-biobank/. All the other datasets used in this study are 782 available in the public domain. 783

784

### 785 Code Availability

Summary-data-based genome-wide Bayesian mixture models are implemented in a public
available software GCTB at <a href="https://cnsgenomics.com/software/gctb/#Download">https://cnsgenomics.com/software/gctb/#Download</a>. Methods to
compute LCS and GCS have also been implemented in GCTB

(https://cnsgenomics.com/software/gctb/#Genome-wideFine-mappinganalysis). Online tool
 for predicting fine-mapping power: https://sbayes.pctgplots.cloud.edu.au/shiny/power/.

791

# 792 Acknowledgements

This research was supported by Australian National Health and Medical Research Council
(1177268, 1113400), the Australian Research Council (FL180100072) and the National Institute

- of Mental Health (5R01MH121545-05). This study makes use of data from the UK Biobank (project ID: 12505).
- 797

# 798 Author Contributions

- J.Z. conceived and supervised the study. J.Z. and Y.W. developed the methods. J.Z., P.M.V. and Y.W.
- designed the experiment. Y.W. conducted all analyses with the assistance or guidance from J.Z.,
- 801 Z.Z., L.T., P.M.V., N.R.W. and M.E.G.. Y.W., and J.Z. wrote the manuscript with the participation of
- all authors. All the authors approved the final version of the manuscript.
- 803

# 804 **Competing Interests**

- 805 The authors declare no competing interests.
- 806

# 807 **References**

- Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation. *The American Journal of Human Genetics* 101, 5-22, doi:10.1016/j.ajhg.2017.06.005 (2017).
- Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. *Am J Hum Genet* 90, 7-24, doi:10.1016/j.ajhg.2011.11.029 (2012).
- Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS discovery:
  Realizing the promise. *Am J Hum Genet* **110**, 179-194, doi:10.1016/j.ajhg.2022.12.011
  (2023).
- 815 4 Uffelmann, E. *et al.* Genome-wide association studies. *Nature Reviews Methods Primers* 1,
  816 59, doi:10.1038/s43586-021-00056-9 (2021).
- Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
  Linkage Analyses. *The American Journal of Human Genetics* 81, 559-575,
  doi:https://doi.org/10.1086/519795 (2007).
- Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics
  identifies additional variants influencing complex traits. *Nature Genetics* 44, 369-375,
  doi:10.1038/ng.2213 (2012).

- Wu, Y., Zheng, Z., Visscher, P. M. & Yang, J. Quantifying the mapping precision of genomewide association studies using whole-genome sequencing data. *Genome Biology* 18, 86,
  doi:10.1186/s13059-017-1216-0 (2017).
- 8 Farh, K. K.-H. *et al.* Genetic and epigenetic fine mapping of causal autoimmune disease
  variants. *Nature* 518, 337-343, doi:10.1038/nature13835 (2015).
- Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal
  variants by statistical fine-mapping. *Nature Reviews Genetics* 19, 491-504,
  doi:10.1038/s41576-018-0016-z (2018).
- 831 10 Stephens, M. False discovery rates: a new deal. *Biostatistics* 18, 275-294,
  832 doi:10.1093/biostatistics/kxw041 (2016).
- Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable 11 833 Selection in Regression, with Application to Genetic Fine Mapping. Journal of the Royal 834 835 Statistical Society Series *B:* Statistical Methodology 82, 1273-1300, doi:10.1111/rssb.12388 (2020). 836
- Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genomewide association studies. *Bioinformatics* 32, 1493-1501,
  doi:10.1093/bioinformatics/btw018 (2016).
- Cui, R. *et al.* Improving fine-mapping by modeling infinitesimal effects. *Nature Genetics*,
  doi:10.1038/s41588-023-01597-3 (2023).
- 842 14 Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data with Single Effects" model. PLOS 18, 843 the "Sum of Genetics e1010299, 844 doi:10.1371/journal.pgen.1010299 (2022).
- Chen, W. *et al.* Fine Mapping Causal Variants with an Approximate Bayesian Method Using
  Marginal Test Statistics. *Genetics* 200, 719-736, doi:10.1534/genetics.115.176107 (2015).
- Yang, Z. *et al.* CARMA is a new Bayesian model for fine-mapping in genome-wide
  association meta-analyses. *Nature Genetics* 55, 1057-1065, doi:10.1038/s41588-02301392-0 (2023).
- Kichaev, G. *et al.* Integrating Functional Data to Prioritize Causal Variants in Statistical
  Fine-Mapping Studies. *PLOS Genetics* 10, e1004722, doi:10.1371/journal.pgen.1004722
  (2014).
- Kichaev, G. & Pasaniuc, B. Leveraging Functional-Annotation Data in Trans-ethnic FineMapping Studies. *The American Journal of Human Genetics* 97, 260-271,
  doi:<u>https://doi.org/10.1016/j.ajhg.2015.06.007</u> (2015).
- Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of
  complex trait heritability. *Nature Genetics* 52, 1355-1363, doi:10.1038/s41588-02000735-5 (2020).

| 859 | 20 | Zhang, Y., Qi, G., Park, JH. & Chatterjee, N. Estimation of complex effect-size distributions |
|-----|----|---|
| 860 |    | using summary-level statistics from genome-wide association studies across 32 complex         |
| 861 |    | traits. <i>Nature Genetics</i> <b>50</b> , 1318-1326, doi:10.1038/s41588-018-0193-x (2018).   |

- Erbe, M. *et al.* Improving accuracy of genomic predictions within and between dairy cattle
  breeds with imputed high-density single nucleotide polymorphism panels. *J Dairy Sci* 95,
  4114-4129, doi:10.3168/jds.2011-5019 (2012).
- MacLeod, I. M. *et al.* Exploiting biological priors and sequence variants enhances QTL
  discovery and genomic prediction of complex traits. *BMC Genomics* 17, 144,
  doi:10.1186/s12864-016-2443-6 (2016).
- Habier, D., Fernando, R. L., Kizilkaya, K. & Garrick, D. J. Extension of the bayesian alphabet
  for genomic selection. *BMC Bioinformatics* 12, 186, doi:10.1186/1471-2105-12-186
  (2011).
- Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple regression on
  summary statistics. *Nature Communications* **10**, 5086, doi:10.1038/s41467-019-126530 (2019).
- Cleveland, M. A., Forni, S., Deeb, N. & Maltecca, C. Genomic breeding value prediction using
  three Bayesian methods and application to reduced density marker panels. *BMC Proceedings* 4, S6, doi:10.1186/1753-6561-4-S1-S6 (2010).
- Moser, G. *et al.* Simultaneous Discovery, Estimation and Prediction Analysis of Complex
  Traits Using a Bayesian Mixture Model. *PLOS Genetics* 11, e1004969,
  doi:10.1371/journal.pgen.1004969 (2015).
- Zheng, Z. *et al.* Leveraging functional genomic annotations and genome coverage to
  improve polygenic prediction of complex traits within and between ancestries. *Nature Genetics*, doi:10.1038/s41588-024-01704-y (2024).
- Xiang, R. *et al.* Genome-wide fine-mapping identifies pleiotropic and functional variants
  that predict many traits across global cattle populations. *Nature Communications* 12, 860,
  doi:10.1038/s41467-021-21001-0 (2021).
- Shrestha, M. *et al.* Evaluation of Bayesian Linear Regression Models as a Fine Mapping
   tool. *bioRxiv*, 2023.2009.2001.555889, doi:10.1101/2023.09.01.555889 (2024).
- Carbonetto, P. & Stephens, M. Scalable Variational Inference for Bayesian Variable
  Selection in Regression, and Its Accuracy in Genetic Association Studies. *Bayesian Analysis* **7**, 73-108, 136 (2012).
- 31 Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex
  traits. *Nature Genetics* 50, 746-753, doi:10.1038/s41588-018-0101-4 (2018).

- Zeng, J. *et al.* Widespread signatures of natural selection across human complex traits and
  functional genomic categories. *Nature Communications* 12, 1164, doi:10.1038/s41467021-21446-3 (2021).
- Spain, S. L. & Barrett, J. C. Strategies for fine-mapping complex traits. *Human Molecular Genetics* 24, R111-R119, doi:10.1093/hmg/ddv260 (2015).
- Gong, Y., Greenbaum, J. & Deng, H. W. A statistical approach to fine-mapping for the
  identification of potential causal variants related to human intelligence. *J Hum Genet* 64,
  781-787, doi:10.1038/s10038-019-0623-3 (2019).
- 35 Kamiza, A. B. *et al.* Multi-trait discovery and fine-mapping of lipid loci in 125,000
  individuals of African ancestry. *Nature Communications* 14, 5403, doi:10.1038/s41467023-41271-0 (2023).
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 906 37 Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
  907 association summary statistics. *Nature Genetics* 47, 1228-1235, doi:10.1038/ng.3404
  908 (2015).
- Gazal, S. *et al.* Functional architecture of low-frequency variants highlights strength of
  negative selection across coding and non-coding annotations. *Nature Genetics* 50, 16001607, doi:10.1038/s41588-018-0231-8 (2018).
- 912 39 Hou, K. *et al.* Causal effects on complex traits are similar for common variants across
  913 segments of different continental ancestries within admixed individuals. *Nature Genetics*914 55, 549-558, doi:10.1038/s41588-023-01338-6 (2023).
- 915 40 Yengo, L. *et al.* A saturated map of common genetic variants associated with human height.
  916 *Nature* 610, 704-712, doi:10.1038/s41586-022-05275-y (2022).
- 917 41 Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
  918 schizophrenia. *Nature* 604, 502-508, doi:10.1038/s41586-022-04434-5 (2022).
- de Lange, K. M. *et al.* Genome-wide association study implicates immune activation of
  multiple integrin genes in inflammatory bowel disease. *Nature Genetics* 49, 256-261,
  doi:10.1038/ng.3760 (2017).
- 43 Lee, Sang H., Wray, Naomi R., Goddard, Michael E. & Visscher, Peter M. Estimating Missing
  Heritability for Disease from Genome-wide Association Studies. *The American Journal of*Human Genetics 88, 294-305, doi:10.1016/j.ajhg.2011.02.002 (2011).
- Yang, J., Wray, N. R. & Visscher, P. M. Comparing apples and oranges: equating the power
  of case-control and quantitative trait association studies. *Genet Epidemiol* 34, 254-257,
  doi:10.1002/gepi.20456 (2010).

- 928 45 Novo, I., López-Cortegano, E. & Caballero, A. Highly pleiotropic variants of human traits
  929 are enriched in genomic regions with strong background selection. *Human Genetics* 140,
  930 1343-1351, doi:10.1007/s00439-021-02308-w (2021).
- 46 Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.
  932 *New England Journal of Medicine* **373**, 895-907, doi:10.1056/NEJMoa1502214 (2015).
- 47 Li, A. *et al.* mBAT-combo: A more powerful test to detect gene-trait associations from
  934 GWAS data. *The American Journal of Human Genetics* 110, 30-43,
  935 doi:https://doi.org/10.1016/j.ajhg.2022.12.006 (2023).
- 48 Li, S. *et al.* The schizophrenia-associated missense variant rs13107325 regulates
  937 dendritic spine density. *Transl Psychiatry* 12, 361, doi:10.1038/s41398-022-02137-z
  938 (2022).
- 939 49 Singh, T. *et al.* Rare coding variants in ten genes confer substantial risk for schizophrenia.
  940 *Nature* 604, 509-516, doi:10.1038/s41586-022-04556-w (2022).
- 941 50 Dai, Z.-M. *et al.* SECISBP2L-Mediated Selenoprotein Synthesis Is Essential for Autonomous
  942 Regulation of Oligodendrocyte Differentiation. *The Journal of Neuroscience* 42, 5860-5869,
  943 doi:10.1523/jneurosci.2141-21.2022 (2022).
- Sazonovs, A. *et al.* Large-scale sequencing identifies multiple genes and rare variants
  associated with Crohn's disease susceptibility. *Nature Genetics* 54, 1275-1283,
  doi:10.1038/s41588-022-01156-2 (2022).
- 947 52 Hutchinson, A., Watson, H. & Wallace, C. Improving the coverage of credible sets in
  948 Bayesian genetic fine-mapping. *PLOS Computational Biology* 16, e1007829,
  949 doi:10.1371/journal.pcbi.1007829 (2020).
- Samaddar, A., Maiti, T. & de los Campos, G. Bayesian Hierarchical Hypothesis Testing in
  Large-Scale Genome-Wide Association Analysis. *bioRxiv*, 2024.2002.2026.582204,
  doi:10.1101/2024.02.26.582204 (2024).
- 953 54 O'Connor, L. J. *et al.* Extreme Polygenicity of Complex Traits Is Explained by Negative
  954 Selection. *The American Journal of Human Genetics* 105, 456-476,
  955 doi:10.1016/j.ajhg.2019.07.003 (2019).
- S5 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex
  trait gene targets. *Nature Genetics* 48, 481-487, doi:10.1038/ng.3538 (2016).

958



**Figure 1** Schematic overview of genome-wide fine-mapping analysis using GBMM. GBMM requires the GWAS summary statistics and genome-wide LD reference to fine-map the likely causal variants for complex traits, and can incorporate functional annotations. Compared to regional-based fine-mapping approaches, GBMM estimates priors with genome-wide SNPs and MCMC sampling algorithm, and is more flexible on the assumption of the underlying distribution of causal effects (**Table S1**). The illustration was created with BioRender.com.





Figure 2 Comparison in the calibration of PIP between GBMM and existing fine-mapping methods
under simulations with various genetic architectures. Shown are relationship between PIP and
the true discovery rate across 100 PIP bins. Results showed in each column correspond to the
results from GBMM (SBayesC and SBayesRC), SuSiE-inf and FINEMAP-inf and SuSiE and
FINEMAMP respectively. Results shown in each row correspond to the sparse genetic
architecture, major gene genetic architecture and LDMS architecture respectively.



975

Figure 3 Comparison in local credible set (LCS) between SBayesRC and SuSiE-inf. Shown in
panels (a-c) are power comparison between SBayesRC and SuSiE-inf at the same alpha cutoff.
Shown in panels (d-f) are credible size comparison between SBayesRC and SuSiE-inf at the same
alpha cutoff. Results showed in each column correspond to the simulation under sparse model (a,
and d), major gene model (b and e) and LDMS model (c and f).





Figure 4 Comparisons of mapping precision, independent sample replication, and effect size
estimation bias among fine-mapping methods. Panel (a-c) shows the distance between the causal
variants and the SNPs identified by different methods at PIP of 0.9 in simulations based on sparse
(a), large effects (b) and LDMS (c) genetic architectures (Methods). Panel (d-e) show the
replication rate of discovery using different methods at a given PIP threshold in the replication

- 987 sample (x-axis) using simulations (d) and real data analysis for height in the UKB (e). Simulations
- are based on a sparse model and results in (d) are the mean values over ten simulation replicates.
- 989 Panel (f-g) show the regression of the estimated marginal effect size in replication samples on the
- 990 estimated joint effect size in discovery samples using different fine-mapping methods. Dash line
- shows the regression slope, which is closer to one for a less biased method. The marginal effect
- estimated in the independent replication samples was used as a proxy to the true value because
- it is an unbiased estimate. The brown solid line is the y=x line.



995

**Figure 5** Out-of-sample prediction accuracy using identified variants from different fine-mapping 996 methods. (a) Comparison of the prediction R<sup>2</sup> using the fine-mapped SNPs from different methods 997 in the simulation based on the sparse architecture (Methods). The number above each bar is the 998 number of fine-mapped SNPs from each method at different PIP cut-offs. (b) Comparison of trans-999 ancestry prediction accuracy using fine-mapped variants from SBayesRC and SuSiE-inf from the 1000 1001 analysis of samples of European ancestry for 6 complex traits in the UK Biobank, with variants with PIP > 0.9. (c) The relationship between trans-ancestry prediction transferability and PIP in 1002 European ancestry. The transferability was computed as non-EUR-R<sup>2</sup>/EUR-R<sup>2</sup>. The solid lines are 1003 regression lines across traits in each ancestry. Results are the mean values over 100 simulation 1004 replicates. 1005





Figure 6 Projection of genome-wide fine-mapping outcomes to the theoretical power prediction 1007 in complex traits with diverse genetic architectures. (a-c) show the results of SBayesRC 1008 estimation for the SNP-based heritability  $(h_{SNP}^2)$  (a), the proportions of  $h_{SNP}^2$  explained by 1009 different mixture components (b), and the proportions of SNPs with effects from different 1010 1011 mixture components ( $\pi$ ) (c), for the simulated trait, height, Crohn's disease (CD), schizophrenia (SCZ), and high density lipoprotein (HDL). (d-e) shows the theoretical prediction of the power of 1012 identifying causal variants (d) and the proportion of  $h_{SNP}^2$  explained by the identified causal 1013 variants at different GWAS sample sizes for these traits. Dot shows the observed trait outcome 1014 based on local credible sets (including singleton LCSs) identified from SBayesRC. Note that the 1015 1016 results shown in (a, c) were used as input data for our method that predicts fine-mapping power 1017 given sample sizes (d-e).



1018

**Figure 7** Theoretical identification and prediction of genome-wide credible SNPs across 48 independent complex traits. Panel (a-b) shows the theoretical prediction of power and proportion of SNP-based heritability explained by GCS SNPs at different GWAS sample sizes for the 48 complex traits, respectively. Panel (c) shows the proportion of identified GCS SNPs at different alpha threshold (proportion of causal variants captured) for the 48 complex traits (average sample size = 291K). Panel (d) shows the proportion of  $h_{SNP}^2$  explained by the GCS SNPs at different alpha threshold. Colours indicate different trait categories.



1027

Figure 8 Genome-wide fine-mapping with functional annotations helped pinpoint the putative causal variants. Panel (a) shows enrichment of the genome-wide fine-mapped SNPs from SBayesRC and GWAS clumped SNPs in the 22 main functional categories defined in the LDSC baseline model. Panel (b) shows the prioritized causal variant at the *FTO* locus for BMI. The top track shows the *FTO* locus plot of the standard GWAS for BMI, and the second track shows the

similar plot but with the PIP from SBayesRC for BMI. The starred SNP is the known causal variant 1033 (rs1421085) for obesity at the *FTO* locus supported by previous functional studies. Panel (c) 1034 shows the per-SNP heritability enrichment for the causal variant (rs1421085), the GWAS lead 1035 variant (rs11642015) and the secondary signal (rs76488452) for BMI at the FTO locus. The 1036 annotations on the x-axis were those present at least once in these three variants, excluding 1037 quantitative annotations and duplicated annotations with flanking windows. Panel (d) shows the 1038 prioritized causal variant at the *SLC39A8* locus for SCZ. The top track shows the *SLC39A8* locus 1039 1040 plot of the standard GWAS for SCZ, and the second track shows the similar plot but with the PIP from SBayesRC for SCZ. The starred SNP is the missense variant (rs13107325) fine-mapped for 1041 SCZ at the SLC39A8 locus. Panel (e) shows the per-SNP heritability enrichment for the causal 1042 variant (rs13107325) and the secondary signal (rs34333163) for SCZ at the SLC39A8 locus. 1043 1044